Hyperkinetic Seizures in Insular and Insulo-Opercular Seizure Onset: A Systematic Review.

Clin EEG NeurosciJun 19, 2026 (epub)
Clinical ResearchNeurology

Rene Andrade Machado, Natasha Acosta Diaz, Satyanarayana Gedela

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined hyperkinetic seizures (HKS) in people with pure insular or insulo-opercular seizure onset, using reports and retrospective series with invasive recording and postsurgical outcome criteria. Fourteen studies comprising 34 patients were included; 61.8% had pure insular onset, and focal cortical dysplasia was the most common etiology, reported in two-thirds. Most seizures began with non-motor features (76.5%). Pure insular onset was associated with more integrated/natural hyperkinetic behaviors, agitation, vocalization, and breathing difficulties than insulo-opercular onset. The authors consider these findings exploratory.

Key findings

  • Across 14 studies and 34 patients, 61.8% had pure insular seizure onset.
  • Focal cortical dysplasia was the most common etiology, present in two-thirds of cases.
  • Most HKS began with non-motor semiology (76.5%).
  • Pure insular onset was associated with more type 3 hyperkinetic automatisms and with agitation, vocalization, and breathing difficulties (p < 0.05).

Why it matters

The review highlights that HKS can occur with insular as well as insulo-opercular seizure onset, and that associated behaviors may differ by onset location. Recognising non-motor beginnings and the range of hyperkinetic features may help clinicians consider these seizure patterns when interpreting semiology. The small, heterogeneous evidence base means these patterns should inform assessment cautiously rather than be treated as definitive.

What to keep in mind

The evidence came from only 14 studies and 34 patients, with heterogeneous reports and retrospective series; the authors describe the findings as exploratory.

Source

Published in Clin EEG Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.